Drug Profile
CZEN 003
Alternative Names: CZEN-003Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Zengen
- Class
- Mechanism of Action Alpha-MSH stimulants; Immunosuppressants; Melanocortin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Transplant-rejection in USA (Injection)
- 13 Jul 2004 This compound is still in active development - BIO 2004 Annual International Convention (BIO-2004)
- 16 Dec 2002 Preclinical trials in Transplant rejection in USA (unspecified route)